ICON Appoints Elizabeth Thomas as Vice President and General Manager of UK Bioanalytical Operations
Dublin, Ireland, May 16th, 2011 – ICON plc, (NASDAQ: ICLR; ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced the appointment of Elizabeth Thomas as Vice President and General Manager of ICON’s Bioanalytical Operations in Manchester, UK.
Ms. Thomas has over 30 years’ experience in bioanalysis and joins ICON from AstraZeneca, where she was Global Discipline Leader, Bioanalysis. In this role she led AstraZeneca’s global Bioanalysis group and the company’s bioanalytical and biomarker laboratory in Manchester, UK, providing an international bioanalysis resource to AstraZeneca’s safety assessment and clinical functions. Prior to AstraZeneca, Ms. Thomas managed the bioanalytical groups at both Quintiles and Covance
Commenting on the appointment, Brian O’Dwyer, Vice President Bioanalytical Development, ICON Development Solutions, said “We are pleased to welcome Liz and the significant commercial, operational and strategic experience she brings to our bioanalytical sciences business. Whilst Liz’s principal focus and responsibility will be the general management of our UK laboratory operations, she will also play a major role in harmonising and expanding our bioanalytical capabilities globally.”
ICON has also boosted its Immunoassay capabilities through the appointment of Dr. Tony Upton, who has joined ICON as Associate Director of Immunoassay Services, EU. Dr. Upton joins ICON from Emergent Limited where he managed the company’s internal live and protein based vaccine laboratory whilst overseeing external contract laboratories supporting Emergent's development programs.
About ICON plc ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. ICON currently has almost 8,000 employees, operating from 77 locations in 38 countries.
Further information is available at www.iconplc.com